Chargement en cours...
First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
SIMPLE SUMMARY: There is a growing body of literature demonstrating high cancer drug costs relative to the benefits provided to patients treated on a large scale. We examined the cost-effectiveness of atezolizumab–bevacizumab for the first-line treatment of patients with unresectable hepatocellular...
Enregistré dans:
| Publié dans: | Cancers (Basel) |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7956424/ https://ncbi.nlm.nih.gov/pubmed/33668100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13050931 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|